Back to Search
Start Over
Biomarkers of Alzheimer's disease in Black and/or African American Alzheimer's Disease Neuroimaging Initiative (ADNI) participants.
- Source :
-
Neurobiology of Aging . Nov2023, Vol. 131, p144-152. 9p. - Publication Year :
- 2023
-
Abstract
- Majority of dementia research is conducted in non-Hispanic White participants despite a greater prevalence of dementia in other racial groups. To obtain a better understanding of biomarker presentation of Alzheimer's disease (AD) in the non-Hispanic White population, this study exclusively examined AD biomarker abnormalities in 85 Black and/or African American participants within the Alzheimer's Disease Neuroimaging Initiative (ADNI). Participants were classified by the ADNI into 3 clinical groups: cognitively normal, mild cognitive impairment, or dementia. Data examined included demographics, apolipoprotein E (APOE) ε4, cerebrospinal fluid (CSF) Aβ 1-42 , CSF total tau (t-tau), CSF phosphorylated tau (p-tau), 3T magnetic resonance imaging (MRI), and measures of cognition and function. Analyses of variance and covariance showed lower cortical thickness in 5 of 7 selected MRI regions, lower hippocampal volume, greater volume of white matter hyperintensities, lower measures of cognition and function, lower measures of CSF Aβ 1 -42 , and greater measures of CSF t-tau and p-tau between clinical groups. Our findings confirmed greater AD biomarker abnormalities between clinical groups in this sample. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 01974580
- Volume :
- 131
- Database :
- Academic Search Index
- Journal :
- Neurobiology of Aging
- Publication Type :
- Academic Journal
- Accession number :
- 172292792
- Full Text :
- https://doi.org/10.1016/j.neurobiolaging.2023.07.021